Tuesday, October 13, 2026

Carnival Stock Went Down By Over 3% At Session Start Today

ViaNews Editorial Team

November 30, 2020

Carnival Stock Went Down By Over 3%  At Session Start Today

Shares of Carnival slid 3.06% to $20.92 at 09:55 EST on Monday, after three consecutive sessions in a row of gains. The New York Stock Exchange is jumping 0.05% to $14,198.50, following yesterday's upward trend, on what up to now seems, a somewhat positive trend exchanging session today.

Carnival's last close was $20.65, 148.28% below its 52-week high of $51.94.

Carnival's sales growth is a negative 96.3% for the ongoing quarter and a decline by 91.6% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 403.2% and a negative 845.5%, respectively.

Year-on-year quarterly revenue growth declined by 99.5%, now sitting on 10.34B for the twelve trailing months.

Carnival's stock is valued at $20.92 at 09:55 EST, way under its 52-week high of $51.94 and way higher than its 52-week low of $7.80.

Carnival's value is way higher than its 50-day moving average of $15.51 and way above its 200-day moving average of $15.85.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com